QQQ   389.91 (+0.72%)
AAPL   163.76 (-0.61%)
MSFT   329.49 (-0.18%)
FB   310.39 (-0.07%)
GOOGL   2,859.32 (+1.36%)
AMZN   3,437.36 (-0.18%)
TSLA   1,084.60 (-0.95%)
NVDA   321.26 (+2.20%)
BABA   122.00 (-0.40%)
NIO   36.20 (-5.51%)
CGC   10.36 (+4.23%)
AMD   150.68 (+1.05%)
GE   95.23 (+2.40%)
MU   82.88 (-2.67%)
T   23.05 (+3.69%)
F   19.87 (+1.48%)
DIS   147.20 (+3.55%)
PFE   53.04 (-3.00%)
AMC   30.28 (+5.99%)
ACB   6.14 (+2.16%)
BA   202.38 (+7.54%)
QQQ   389.91 (+0.72%)
AAPL   163.76 (-0.61%)
MSFT   329.49 (-0.18%)
FB   310.39 (-0.07%)
GOOGL   2,859.32 (+1.36%)
AMZN   3,437.36 (-0.18%)
TSLA   1,084.60 (-0.95%)
NVDA   321.26 (+2.20%)
BABA   122.00 (-0.40%)
NIO   36.20 (-5.51%)
CGC   10.36 (+4.23%)
AMD   150.68 (+1.05%)
GE   95.23 (+2.40%)
MU   82.88 (-2.67%)
T   23.05 (+3.69%)
F   19.87 (+1.48%)
DIS   147.20 (+3.55%)
PFE   53.04 (-3.00%)
AMC   30.28 (+5.99%)
ACB   6.14 (+2.16%)
BA   202.38 (+7.54%)
QQQ   389.91 (+0.72%)
AAPL   163.76 (-0.61%)
MSFT   329.49 (-0.18%)
FB   310.39 (-0.07%)
GOOGL   2,859.32 (+1.36%)
AMZN   3,437.36 (-0.18%)
TSLA   1,084.60 (-0.95%)
NVDA   321.26 (+2.20%)
BABA   122.00 (-0.40%)
NIO   36.20 (-5.51%)
CGC   10.36 (+4.23%)
AMD   150.68 (+1.05%)
GE   95.23 (+2.40%)
MU   82.88 (-2.67%)
T   23.05 (+3.69%)
F   19.87 (+1.48%)
DIS   147.20 (+3.55%)
PFE   53.04 (-3.00%)
AMC   30.28 (+5.99%)
ACB   6.14 (+2.16%)
BA   202.38 (+7.54%)
QQQ   389.91 (+0.72%)
AAPL   163.76 (-0.61%)
MSFT   329.49 (-0.18%)
FB   310.39 (-0.07%)
GOOGL   2,859.32 (+1.36%)
AMZN   3,437.36 (-0.18%)
TSLA   1,084.60 (-0.95%)
NVDA   321.26 (+2.20%)
BABA   122.00 (-0.40%)
NIO   36.20 (-5.51%)
CGC   10.36 (+4.23%)
AMD   150.68 (+1.05%)
GE   95.23 (+2.40%)
MU   82.88 (-2.67%)
T   23.05 (+3.69%)
F   19.87 (+1.48%)
DIS   147.20 (+3.55%)
PFE   53.04 (-3.00%)
AMC   30.28 (+5.99%)
ACB   6.14 (+2.16%)
BA   202.38 (+7.54%)
NASDAQ:CAPR

Capricor Therapeutics Stock Forecast, Price & News

$3.06
-0.15 (-4.67%)
(As of 12/2/2021 12:00 AM ET)
Add
Compare
Today's Range
$2.94
$3.29
50-Day Range
$3.06
$5.23
52-Week Range
$2.94
$8.40
Volume
405,466 shs
Average Volume
625,616 shs
Market Capitalization
$73.90 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
6.19
30 days | 90 days | 365 days | Advanced Chart
Receive CAPR News and Ratings via Email

Sign-up to receive the latest news and ratings for Capricor Therapeutics and its competitors with MarketBeat's FREE daily newsletter.


Capricor Therapeutics logo

About Capricor Therapeutics

Capricor Therapeutics, Inc. (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor's lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy. Capricor has also established itself as one of the leading companies investigating the field of extracellular vesicles and is exploring the potential of CAP-2003, a cell-free, exosome-based candidate, to treat a variety of disorders.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:CAPR
Employees
N/A
Year Founded
N/A

Sales & Book Value

Annual Sales
$310 thousand
Book Value
$1.38 per share

Profitability

Net Income
$-13.66 million
Net Margins
-5,621.25%
Pretax Margin
-5,943.90%

Debt

Price-To-Earnings

Miscellaneous

Free Float
22,459,000
Market Cap
$73.90 million
Optionable
Not Optionable

Company Calendar

Last Earnings
11/08/2021
Today
12/02/2021
Fiscal Year End
12/31/2021
Next Earnings (Estimated)
3/10/2022

MarketRank

Overall MarketRank

1.55 out of 5 stars

Medical Sector

1052nd out of 1,391 stocks

Pharmaceutical Preparations Industry

499th out of 669 stocks

Analyst Opinion: 3.5Community Rank: 4.3Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -












Capricor Therapeutics (NASDAQ:CAPR) Frequently Asked Questions

Is Capricor Therapeutics a buy right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Capricor Therapeutics in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Capricor Therapeutics stock.
View analyst ratings for Capricor Therapeutics
or view top-rated stocks.

How has Capricor Therapeutics' stock been impacted by COVID-19?

Capricor Therapeutics' stock was trading at $1.0050 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, CAPR shares have increased by 204.5% and is now trading at $3.06.
View which stocks have been most impacted by COVID-19
.

When is Capricor Therapeutics' next earnings date?

Capricor Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, March 10th 2022.
View our earnings forecast for Capricor Therapeutics
.

How were Capricor Therapeutics' earnings last quarter?

Capricor Therapeutics Inc (NASDAQ:CAPR) released its quarterly earnings results on Monday, November, 8th. The biotechnology company reported ($0.17) earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of ($0.22) by $0.05. Capricor Therapeutics had a negative net margin of 5,621.25% and a negative trailing twelve-month return on equity of 53.48%. During the same period in the previous year, the firm posted ($0.20) earnings per share.
View Capricor Therapeutics' earnings history
.

What price target have analysts set for CAPR?

2 equities research analysts have issued 12-month price objectives for Capricor Therapeutics' shares. Their forecasts range from $12.00 to $14.00. On average, they anticipate Capricor Therapeutics' stock price to reach $13.00 in the next year. This suggests a possible upside of 324.8% from the stock's current price.
View analysts' price targets for Capricor Therapeutics
or view top-rated stocks among Wall Street analysts.

Who are Capricor Therapeutics' key executives?

Capricor Therapeutics' management team includes the following people:
  • Frank I. Litvack M.D., Independent Executive Chairman of the Board (Age 59)
  • Linda Marban Ph.D., President, Chief Executive Officer, Director (Age 51)
  • Anthony Bergmann, Chief Financial Officer, Principal Accounting Officer (Age 32)
  • Karen G. Krasney J.D., Executive Vice President, General Counsel (Age 62)
  • Thomas Lyle Copmann Ph.D., Vice President - Regulatory Affairs and Drug Development (Age 61)
  • Houman Hemmati M.D., Ph.D., Vice President - Medical & Clinical Development, New Therapies
  • Luis Rodriguez-Borlado Ph.D., Vice President - Regenerative Therapies
  • Rachel Smith Ph.D., Vice President - Research & Development (Age 36)
  • Deborah Ascheim M.D., Chief Medical Officer
  • Joshua A. Kazam, Director (Age 40)

What other stocks do shareholders of Capricor Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Capricor Therapeutics investors own include Marinus Pharmaceuticals (MRNS), Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), Vaxart (VXRT), Inovio Pharmaceuticals (INO), Trevena (TRVN), Dynavax Technologies (DVAX), Chesapeake Energy (CHKAQ), OPKO Health (OPK) and Advanced Micro Devices (AMD).

What is Capricor Therapeutics' stock symbol?

Capricor Therapeutics trades on the NASDAQ under the ticker symbol "CAPR."

Who are Capricor Therapeutics' major shareholders?

Capricor Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (1.30%), Geode Capital Management LLC (0.89%), Citadel Advisors LLC (0.00%), GSA Capital Partners LLP (0.42%), HighTower Advisors LLC (0.23%) and Morgan Stanley (0.22%).
View institutional ownership trends for Capricor Therapeutics
.

Which major investors are selling Capricor Therapeutics stock?

CAPR stock was sold by a variety of institutional investors in the last quarter, including GSA Capital Partners LLP, and BlackRock Inc..
View insider buying and selling activity for Capricor Therapeutics
or view top insider-selling stocks.

Which major investors are buying Capricor Therapeutics stock?

CAPR stock was bought by a variety of institutional investors in the last quarter, including Citadel Advisors LLC, HighTower Advisors LLC, Dimensional Fund Advisors LP, Goldman Sachs Group Inc., Geode Capital Management LLC, Two Sigma Securities LLC, Morgan Stanley, and Barclays PLC.
View insider buying and selling activity for Capricor Therapeutics
or or view top insider-buying stocks.

How do I buy shares of Capricor Therapeutics?

Shares of CAPR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Capricor Therapeutics' stock price today?

One share of CAPR stock can currently be purchased for approximately $3.06.

How much money does Capricor Therapeutics make?

Capricor Therapeutics has a market capitalization of $73.90 million and generates $310 thousand in revenue each year. The biotechnology company earns $-13.66 million in net income (profit) each year or ($0.82) on an earnings per share basis.

What is Capricor Therapeutics' official website?

The official website for Capricor Therapeutics is www.capricor.com.

Where are Capricor Therapeutics' headquarters?

Capricor Therapeutics is headquartered at 8840 WILSHIRE BLVD 2ND FLOOR, BEVERLY HILLS CA, 90211.

How can I contact Capricor Therapeutics?

Capricor Therapeutics' mailing address is 8840 WILSHIRE BLVD 2ND FLOOR, BEVERLY HILLS CA, 90211. The biotechnology company can be reached via phone at 310-358-3200, via email at [email protected], or via fax at 415-875-7075.


This page was last updated on 12/2/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.